Loading…

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

Saved in:

Bibliographic Details
Published in:	Blood 2024-11, Vol.144 (Supplement 1), p.6664-6664
Main Authors:	Palandri, Francesca, Breccia, Massimo, Morsia, Erika, Benevolo, Giulia, Tiribelli, Mario, Beggiato, Eloise, Farina, Mirko, Martino, Bruno, Caocci, Giovanni, Pugliese, Novella, Tieghi, Alessia, Crugnola, Monica, Binotto, Gianni, Cavazzini, Francesco, Abruzzese, Elisabetta, Isidori, Alessandro, Dedola, Alessandra, Scalzulli, Emilia, Moioli, Alessia, Guglielmana, Veronica, Caserta, Santino, Duminuco, Andrea, Lemoli, Roberto Massimo, Cilloni, Daniela, Bocchia, Monica, Pane, Fabrizio, Heidel, Florian, Elli, Elena Maria, Bonifacio, Massimiliano, Palumbo, Giuseppe Alberto, Branzanti, Filippo
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!